600200 Stock Overview
JiangSu WuZhong Pharmaceutical Development Co., Ltd. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
JiangSu WuZhong Pharmaceutical Development Co., Ltd. Competitors
Sailong Pharmaceutical GroupLtd
Zhejiang Benli Technology
Zhejiang East Asia Pharmaceutical
Jilin Province Xidian Pharmaceutical Sci-Tech DevelopmentLtd
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥2.72 |
| 52 Week High | CN¥11.61 |
| 52 Week Low | CN¥2.26 |
| Beta | 0.14 |
| 1 Month Change | -15.00% |
| 3 Month Change | -62.48% |
| 1 Year Change | -73.02% |
| 3 Year Change | -59.94% |
| 5 Year Change | -56.27% |
| Change since IPO | -51.43% |
Recent News & Updates
Recent updates
JiangSu WuZhong Pharmaceutical Development Co., Ltd.'s (SHSE:600200) Shares Lagging The Industry But So Is The Business
Feb 27
Is JiangSu WuZhong Pharmaceutical Development (SHSE:600200) A Risky Investment?
Jan 14Health Check: How Prudently Does JiangSu WuZhong Pharmaceutical Development (SHSE:600200) Use Debt?
Sep 25Sentiment Still Eluding JiangSu WuZhong Pharmaceutical Development Co., Ltd. (SHSE:600200)
Jul 31JiangSu WuZhong Pharmaceutical Development (SHSE:600200) Is Making Moderate Use Of Debt
Jun 06Many Still Looking Away From JiangSu WuZhong Pharmaceutical Development Co., Ltd. (SHSE:600200)
Mar 12Shareholder Returns
| 600200 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 1.9% | 2.7% | -0.01% |
| 1Y | -73.0% | 11.4% | 10.1% |
Return vs Industry: 600200 underperformed the CN Pharmaceuticals industry which returned 11.4% over the past year.
Return vs Market: 600200 underperformed the CN Market which returned 10.1% over the past year.
Price Volatility
| 600200 volatility | |
|---|---|
| 600200 Average Weekly Movement | 10.0% |
| Pharmaceuticals Industry Average Movement | 5.8% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in CN Market | 10.0% |
| 10% least volatile stocks in CN Market | 4.2% |
Stable Share Price: 600200's share price has been volatile over the past 3 months compared to the CN market.
Volatility Over Time: 600200's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of CN stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 1,096 | Qunshan Qian | www.600200.com |
JiangSu WuZhong Pharmaceutical Development Co., Ltd. engages in pharmaceutical, medical cosmetology, investment, and other industries in China and internationally. It provides genetic and chemical drugs in the fields of anti-virus, anti infection, immune regulation, anti-tumor, digestive system, cardiovascular, etc.; and modern traditional Chinese medicine.
JiangSu WuZhong Pharmaceutical Development Co., Ltd. Fundamentals Summary
| 600200 fundamental statistics | |
|---|---|
| Market cap | CN¥1.92b |
| Earnings (TTM) | -CN¥4.89m |
| Revenue (TTM) | CN¥1.49b |
Is 600200 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 600200 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.49b |
| Cost of Revenue | CN¥666.40m |
| Gross Profit | CN¥823.88m |
| Other Expenses | CN¥828.77m |
| Earnings | -CN¥4.89m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0069 |
| Gross Margin | 55.28% |
| Net Profit Margin | -0.33% |
| Debt/Equity Ratio | 88.7% |
How did 600200 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/31 10:57 |
| End of Day Share Price | 2025/05/30 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
JiangSu WuZhong Pharmaceutical Development Co., Ltd. is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Zhuonan Xu | China International Capital Corporation Limited |
| Hao Jiang | Everbright Securities Co. Ltd. |